Drug intelligence / Profile preview

PL-14

Development stage: Unknown
Lead developer: Polyrizon
Modality: Hydrogel Systems → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration: Intranasal

Overview

PL-14 is an investigational intranasal hydrogel-based allergy blocker developed by Polyrizon. It is designed to be delivered as a nasal spray, forming a thin hydrogel barrier in the nasal cavity that acts as a "biological mask," physically blocking allergens and potentially viruses from contacting the nasal epithelial tissue. The technology, known as Capture and Contain (C&C), uses naturally occurring building blocks to create this protective shield. The product aims to provide non-pharmacological protection against airborne allergens and is being advanced toward clinical trials for allergy prevention or mitigation[1][2].

Brand names: NASARIX
Other names: PL-14PL14PL 14

Beyond the preview

Go deeper on PL-14.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PL-14.

Explore the full profile